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ABSTRACT
Introduction Invasive aspergillosis is the most important 
cause of morbidity and mortality in patients with 
haematological diseases. At present, voriconazole is 
the first- line treatment for invasive fungal disease. The 
pharmacokinetic interindividual variability of voriconazole 
depends on genetic factors. CYP450 is involved in 
70%–75% of total metabolism of voriconazole, mainly 
CYP3A4 and CYP2C19, with the remaining 25%–30% 
of metabolism conducted by monooxygenase flavins. 
CYP2C19 single nucleotide polymorphisms could explain 
50%–55% of variability in voriconazole metabolism.
Materials and methods The main objective is to 
compare efficiency of pre- emptive voriconazole genotyping 
with routine practice. The primary outcome is serum 
voriconazole on the fifth day within the therapeutic range. 
The secondary outcome is the combined variables of 
therapeutic failure and adverse events within 90 days 
of first administration, associated with voriconazole. A 
total of 146 patients at risk of invasive aspergillosis who 
will potentially receive voriconazole will be recruited, 
and CYP2C19 will be genotyped. If the patient ultimately 
receives voriconazole, they will be randomised (1:1 
experimental/control). In the experimental arm, patients 
will receive a dose according to a pharmacogenetic 
algorithm, including CYP2C19 genotype and clinical and 
demographic information. In the control arm, patients will 
receive a dose according to clinical practice guidelines. 
In addition, a Spanish National Healthcare System (NHS) 
point- of- view cost- effectiveness evaluation will be 
performed. Direct cost calculations for each arm will be 
performed.
Conclusion This trial will provide information about the 
viability and cost- effectiveness of the implementation of 
a pre- emptive voriconazole genotyping strategy in the 
Spanish NHS.
Ethics and dissemination A Spanish version of this 
protocol has been evaluated and approved by the La Paz 
University Hospital Ethics Committee and the Spanish 
Agency of Medicines and Medical Devices. Trial results 
will be submitted for publication in an open peer- reviewed 
medical speciality- specific publication.
Trial registration number Eudra- CT: 2019-000376-41 
and NCT04238884; Pre-results.
INTRODUCTION
Invasive aspergillosis is the most important 
cause of morbidity and mortality in patients 
with haematological diseases. The most 
recent epidemiological studies show an 
incidence of probable or proven invasive 
aspergillosis in patients with high- risk haema-
tological diseases of 6%–11%.1 2 Mortality 
due to this complication in patients with 
acute leukaemia is 27%,1 and up to 40% if 
we include every malignant haematological 
disease.3 In recent years, great advances in the 
treatment of this pathology have been made, 
which have improved the prognosis of haema-
tologic diseases. However, high morbidity and 
mortality associated with infectious complica-
tions continue to be a medical problem. As 
a result, improving the prognosis for invasive 
Strengths and limitations of this study
 ► The study will be randomised, with objective 
variables and not influenced by placebo effect 
(voriconazole serum level).
 ► The effectiveness and safety related to serum 
voriconazole is well known.
 ► For patients in this study, there is little risk compared 
with routine clinical practice.
 ► The study is single- blinded.
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fungal disease has great scientific interest, with aspergil-
losis being the most prevalent form.
At present, voriconazole is the first- line treatment for 
invasive fungal disease (1- grade evidence, A- grade recom-
mendation).4 5 It is a third- generation triazole antifungal 
with broad- spectrum activity. Achieving voriconazole 
serum levels in the therapeutic range during the first 
treatment week improves the prognosis of fungal infec-
tion and the tolerability of the treatment by reducing 
dose- dependent adverse effects (AEs).6 The AE reduc-
tion, associated with posology optimisation, decreases the 
amount of withdrawals of this antifungal drug.
Genetic variations could become markers that help 
us predict the pharmacological response depending on 
whether they are present and on their inter- relationship 
with other markers associated with clinical response. 
In recent years, several groups and organisations have 
published evidence assessment systems, guidelines, 
systematic reviews and evaluations for various drugs and 
pathologies; in some cases, genotyping prior to treatment 
with various drugs has been shown to be cost- efficient.7
Focusing on voriconazole, its pharmacokinetic inter-
individual variability depends on genetic factors.8 
CYP450 is involved in 70%–75% of the total metabo-
lism of voriconazole, mainly CYP3A4 and CYP2C19, 
with the remaining 25%–30% of metabolism conducted 
by monooxygenase flavins. CYP2C19 single nucleotide 
polymorphisms could explain 50%–55% of variability 
in voriconazole metabolism. Some 5%–17% of patients 
are ultrafast metabolisers (CYP2C19*17/*17), and 
approximately 25%–33% of patients are fast metabolisers 
(CYP2C19*1/*17). Both are associated with a high risk 
of not achieving therapeutic levels for invasive aspergil-
losis.9 10 Pharmacogenetics information oriented to dose 
adjustment is present in European dosing guidelines and 
in Food and Drug Administration recommendations, in 
which recommendations are given according to geno-
type.8 This information must be known by every physician 
in order to reduce adverse effects, improve effectiveness 
and thus raise patient compliance by reducing morbidity 
and mortality.
We propose a pragmatic clinical trial to evaluate 
the effectiveness and efficiency of a pre- emptive geno-
typing strategy of biomarkers related to the voriconazole 
response in patients with haematological disease who are 




VORIGENIPHARM is an acronym (VORIconazole 
PHARMacoGENetIcs) of the clinical trial, funded by the 
Spanish Health Research and Development Strategy. It is 
a phase IV pragmatic, multicentre, randomised, single- 
blind, parallel arm, centre- stratified clinical trial. A total 
of 146 patients at risk of invasive aspergillosis who will 
potentially receive voriconazole will be recruited, and 
CYP2C19 alleles will be genotyped. The patients who ulti-
mately receive voriconazole will be randomised to receive 
the dose according to a pharmacogenetic algorithm, 
including the CYP2C19 genotype and clinical and demo-
graphic information, or according to clinical practice 
(figure 1).
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Evaluating the effectiveness and efficiency of a pre- 
emptive genotyping strategy for voriconazole in treat-
ment and prophylaxis of Aspergillus fungal infections in 
patients with haematological diseases.
Primary objective
 ► Evaluate the effectiveness of a pre- emptive geno-
typing strategy for voriconazole in achieving adequate 
therapeutic levels in haematological patients at risk 
of fungal infection compared with routine clinical 
practice.
Secondary objectives
 ► Evaluate the safety of pre- emptive genotyping of 
voriconazole in haematological patients at risk of 
fungal infection, comparing it with routine clinical 
practice.
 ► Evaluate the efficiency of this pre- emptive genotyping 
strategy. By mean of a cost- effectiveness analysis. Cost 
includes the mean total direct cost per patient, also 
including the cost of adverse events (AEs). The effec-
tiveness will be measured as a combined variable 
of therapeutic failure described in the ‘Outcomes’ 
section.
Eligibility
The patient will be selected from La Paz University 
Hospital Paediatrics Hemato- Oncology Department, La 
Paz University Hospital Haematology Department, La 
Princesa University Hospital Adult Hematology Depart-
ment and Gomez- Ulla University Hospital Adult Hema-
tology Department. They will include children and adults 
who meet the following inclusion criteria:
1. Risk of developing invasive aspergillosis who are po-
tentially eligible for treatment or prophylaxis with 
voriconazole:
1. Paediatric population: children undergoing haemato-
poietic stem cell transplantation, with acute myeloid 
leukaemia, as well as their relapses.
2. Adult population: patients diagnosed with acute leu-
kaemia and those with long- term expected neutro-
paenia secondary to haematological disease and/or 
undergoing specific treatment (eg, aplastic anaemia 
and variants, myelodysplastic syndrome, solid organ 
or bone marrow transplantation), and patients who 
the clinician in charge considers might be at risk of 
developing fungal infection.
2. Accepting participation in the study by signing the 
informed consent (adult patients), or minor patients 
whose representative/legal guardian has willingly 
signed the informed consent. In the case of mature 
minors (12–17 years of age), in addition to the consent 
signed by the legal guardian, the minor’s assent shall 
be obtained.
The exclusion criteria are as follows:
1. Patients who for any reason should not be included in 
the study as assessed by the research team.
2. Patients who are not capable of understanding the in-
formation form and are unable to sign the informed 
consent document.
All patients eligible to receive voriconazole will sign an 
informed consent document for their participation in 
the clinical trial and for the collection of blood samples 
destined for genetic studies. They will also be asked for 
their consent to store an aliquot of their DNA for future 
studies (ie, mass sequencing). Patients identified in 
this phase will be randomised if and when they receive 
voriconazole.
Randomisation
Patients who meet all inclusion and no exclusion criteria, 
who have signed the informed consent and will receive 
voriconazole will be randomised, stratified by centres. 
The randomisation sequence was created using SAS V.9.4 
statistical software (procedure ‘PROC PLAN’) with a 1:1 
allocation. No randomisation seed was specified. The 
randomisation seed was generated taking the hour of the 
computer where the program was executed. Randomis-
ation will be done centrally through the electronic CRF 
(MACRO) in order to conceal the sequence until inter-
ventions are assigned.
Masking
The study is single blind, and under no circumstance 
does the patient know the group to which they have 
been assigned. The medical researchers are unaware of 
the randomisation scheme. Although there is a risk of 
unmasking the patient, and the lack of masking for the 
physician could affect the evaluation variables, we believe 
that in this clinical trial is permissible since the primary 
variable is an objective one (voriconazole concentration), 




Serum voriconazole levels in the range of 1–5.5 µg/mL on 
the fifth day, according to the British Society for Medical 
Mycology, which is a subrogated variable strongly related 
to effectiveness and safety, with high- level evidence.11
Secondary outcomes
 ► A combined variable of therapeutic failure and 
AEs occurring within 90 days of first voriconazole 
administration.
 – Therapeutic failure is defined following European 
Organisation for Research and Treatment of 
Cancer (EORTC) consensus12:
 – Patients with probable or proven invasive asper-
gillosis: drug change or association because of 
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 – Patients who received prophylactic treatment: 
the necessity of change because of probable or 
proven invasive fungal disease.
 – AE: dose- dependent drug AEs, including visual 
disturbances (eg, photopsia), skin reactions, neu-
rotoxicity (eg, confusion and visual hallucinations) 
and QTc lengthening, requiring voriconazole 
withdrawal.
 ► Costs by AE.
 ► Cost savings by AE.
 ► Quality- adjusted life years.
Study procedures
The study visits and procedures will be performed as 
shown in table 1.
 ► Selection visit: after confirming the selection criteria, 
informing the patient and signing the informed 
consent document, a blood sample will be taken 
for genetic analysis. Patients who have not received 
voriconazole within 3 months of recruitment will not 
be considered for randomisation, but will be consid-
ered for economic evaluation. Patients who, in this 
3- month period, receive voriconazole will continue to 
the randomisation visit.
 ► Randomisation visit: the patient will be randomised to 
one of the two branches of the study:
 – Experimental group: based on the genetic study 
performed and the patient’s characteristics (age, 
weight, indication), the Pharmacogenetics Unit 
of La Paz University Hospital will indicate the 
dose to be administered. The dose will be based 
on the therapeutic individualisation protocol guid-
ed by pharmacogenetics, as agreed by all clinical 
services, and which includes the recommendations 
of the Clinical Pharmacogenetics Implementation 
Consortium guide (Moriyana, 2016) and the study 
by Hicks et al. In the experimental group arm, in 
cases of patients with rapid, ultrafast or slow me-
taboliser phenotypes, a determination of serum 
voriconazole concentrations at 48 hours (±24 
hours) may be considered, which will make a dose 
adjustment possible if required.
 – Control group: no information will be provided and 
the procedure will be performed according to nor-
mal clinical practice, with clinical monitoring by 
the doctor in charge. In both cases, the request 
for serum voriconazole levels for subsequent dose 
adjustment will be recommended, as is standard 
clinical practice, in accordance with the recom-
mendations of the British Society for Medical 
Mycology.6
 ► Primary outcome evaluation visit: voriconazole concen-
trations will be measured on no later than the fifth day 
after the start of treatment (±1 day); if a dose adjust-
ment is necessary, this will be performed according to 
the criteria of the attending clinician (control group) 
or the pharmacogenetic unit (experimental group); 
subsequent monitoring (determination of concen-
trations and dose adjustment) will be performed 
according to the criteria of the attending clinician in 
both arms.
 ► Follow- up visits: while the patient is being treated with 
voriconazole, follow- up visits will be made according 
to clinical criteria, and the following information will 
be recorded:










End- of- treatment 
visit End- of- study visit




Fifth day of 
treatment (±1 day)
Weekly 
until end of 
treatment
Last day of 
treatment













X   X†
Lab analysis‡ X X X X X
Electrocardigram X X X X X
AE evaluation X X X X X
*Patients who after 3 months continue being treated, End- of- study visit will be done on the last day of third month.
†According to physician criteria.
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 – Evaluation of potential voriconazole- related clin-
ical AEs (see evaluation variables). This will be 
performed by asking the patient questions, per-
forming a physical examination, routine tests (in-
cluding liver enzymes) and an ECG.
 – Voriconazole levels, if requested according to med-
ical criteria.
 – The type of consultation will be recorded: outpa-
tient appointment, urgent episode, admission, re-
admission or phone call.
 ► End- of- treatment visit: performed on the last day 
the patient receives treatment with voriconazole, 
including the following procedures:
 – A reason for the end of treatment will be indicated 
(withdrawal due to toxicity or therapeutic failure, 
or after completion of treatment according to clin-
ical criteria of efficacy).
 – Evaluation of potentially voriconazole- related clini-
cal AEs, as in follow- up visits.
 – If the patient continues voriconazole treatment be-
yond 3 months, the end- of- study visit will be made 
at that time.
 ► End- of- study visit: the end- of- study visit will coin-
cide with the end- of- treatment visit, except for those 
patients who are still undergoing treatment after 
3 months. A safety analysis, ECG and assessment of 
AEs will be performed. Patients who continue treat-
ment beyond this visit will be followed according to 
routine clinical practice.
Voriconazole genotyping and therapeutic drug monitoring
Genotyping will be performed at the Institute of Medical 
and Molecular Genetics at La Paz University Hospital 
using the self- designed SNP- array device (PharmArray 
V.2.), which makes genotyping of 180 relevant mutations 
possible for predicting the response to drugs. Among 
these mutations are the most relevant variants of CYP2C19, 
a gene that is related to serum levels of voriconazole, with 
a level of evidence 1A of CPIC: CYP2C19*2 (rs4244285), 
CYP2C19*3 (rs4986893) and CYP2C19*17 (rs12248560).
Serum voriconazole determinations will be tested at the 
Therapeutic Drug Monitoring Laboratory of the Clinical 
Pharmacology Service at La Paz University Hospital using 
an enzyme immunosensing technique on the Abbott 
ARCHITECT c4000 autoanalyser.
Data collection and outcome measures
A electronic case report form (eCRF) has been designed 
using MACRO Electronic Data Capture by Elsevier. This 
eCRF will include all the variables described and also 
concomitant medication and other clinical and demo-
graphic condition that could interfere with voriconazole. 
This system will anonymise patients, and the data will be 
transferred to a ‘*.csv’ file in order to analyse it with R 
software (V.3.5.2 or newer). To ensure the quality of the 
data, data management will be performed by the Spanish 
Clinical Research Network (SCReN). Data management 
plan have been approved by the principal investigator 
and the sponsor. Data collection forms will be included 
in the final report.
Sample size calculation
In routine clinical practice, 43% of patients have 
voriconazole serum levels in the therapeutic range on the 
fifth day of treatment. We expect this to improve to 68%, 
based on the article by Hicks et al.9 With a two- tailed type 
I error of 0.05% and 80% power, it is necessary to recruit 
62 patients to receive treatment in both arms. Eighty- 
five out of every 100 patients recruited are estimated to 
receive voriconazole, we will need a total of 146 patients 
from whom we obtain informed consent. This calculation 
has been performed with the ‘ power. prop. test’ package, 
from R V.3.2.0. The necessary time to recruit the whole 
group is estimated to be 2 years. We estimate 20% of the 
patients will be selected from the La Princesa University 
Hospital Adult Haematology Department, and 20% from 
the Gomez- Ulla University Hospital Adult Haematology 
Department. The rest of group will be recruited from 
La Paz University Hospital. Since it is a phase IV clinical 
trial including patients that are usually followed in the 
hospital, with pragmatic selection criteria, it is not neces-
sary to plan any strategy for achieving adequate partici-
pant enrolment.
Statistical analysis
Frequency results will be expressed in absolute terms, 
as percentages and CIs. Continuous variables will be 
expressed as mean (SD) and median (range) according 
to Kolmogorov- Smirnov test of normality.
For the main dichotomous variable (level of 
voriconazole within the therapeutic range), a generalised 
logistic model will be used. After that, ‘elastic net’ tech-
niques will be employed with the purpose of selecting 
variables so that they are not as rigid as in Lasso’s case. 
Variables with some degree of correlation between them-
selves will be accepted in the model, as in Ridge regres-
sion, aiming at the best possible predictive model. Finally, 
more advanced methods of statistical learning will be used 
to give the variables consistency by the method described 
above. Predictive ability will be calculated using receiver 
operating characteristic curves both at a specific time and 
over the course of the patient’s follow- up.
A survival analysis will be performed for the secondary 
variables to test the Cox proportional hazards model and 
the Weibull model, analysing the time until the first event, 
using Kaplan- Meier curves. A penalised Cox regression 
will be fitted to determine whether there are differences 
from the start of the target drug to the appearance of the 
event (secondary variable) between the control group 
and the experimental group, and finally, if possible the 
Weibull model will be used. A cross- validation approach 
will be used, dividing the sample into k subgroups. Later, 
a subgroup analysis will be performed taking into consid-
eration the recruiting centre, calculating the a posteriori 
analysis power of every objective, given that this can be a 
source of hypothesis generation for future research lines.
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The analysis of the primary variable of efficacy will be 
made on an intention- to- treat basis. It will include all the 
patients who are randomised, whether they have received 
the study treatment or not. The safety analyses will be 
held in the safety population, which includes patients 
who receive at least one dose of the drug during the study. 
No interim analysis or stopping rules will be carry out in 
this clinical trial.
A bilateral significance level of 0.05 and bilateral 95% 
CIs will be assumed. The statistical software R (R Core 
Team (2014)) will be used. R: A language and environ-
ment for statistical computing. R Foundation for Statis-
tical Computing, Vienna, Austria.
Economic evaluation
A Spanish National Healthcare Service (NHS) point- 
of- view cost- effectiveness evaluation will be performed. 
Direct cost calculations for each arm will be performed.
Direct costs will be calculated for both alternatives 
by registering healthcare resources used during the 
follow- up and the unit cost per patient, as well as the costs 
incurred by the centres to implement the intervention.
The use of resources and their unit costs, such as doctor’s 
visits, medications and any interventions performed on 
those patients in the hospital during follow- up shall be 
recorded. Costs for each patient for each intervention 
group will be totalled. This calculation will allow us to 
compare the average cost per event avoided between the 
intervention group and the control group. The results 
will be expressed in cost per event and avoided events. As 
far as possible, the utility of each intervention should be 
calculated.
A univariate and a probabilistic sensitivity analysis will 
be performed to assess the uncertainty about the model 
and the unit costs, if they are obtained from a source 
other than the clinical centres.
Data monitoring
Coordination, management, monitoring, data manage-
ment and statistical analysis of the study will be performed 
by the SCReN.
Auditing
During the progress of the study, audit visits can be 
conducted at the participating centres. The investigator 
will allow direct access to the source data/documents 
for monitoring, auditing, review by the ethical research 
committee and inspection by the health authorities.
Conflicts of interest
The funders and sponsor not interfere in the selection 
processes of the patients, analysis of the data and/or 
publication of the results, or any other process that might 
come into play with the results of the study. Funding will 
be independent of the results of the study. The Principal 
Investigator has ultimate authority over any of these 
activities.
Patient and public involvement
The development of the research question and outcome 
measures were based on the oncologists’ experience 
treating this profile of patients the desire to optimise 
voriconazole treatment. Patients and patient advisers 
were not involved in the design, recruitment or conduct 
of this study. The patients or their families will be notified 
of the study results in writing and verbally, and we will 
invite them to help us develop our dissemination strategy.
Access to data
This section is included in the data sharing plan.
Dissemination policy
Outputs from this study will include journal publications, 
conference presentations and community reporting. 
Outputs will not identify participants.
Ethical considerations
The researchers will adhere strictly to the provisions of 
this protocol and will complete the case report forms. 
The study will be performed according to the recommen-
dations for clinical studies and the evaluation of drugs 
in humans, as contained in the Declaration of Helsinki 
(revised in successive world assemblies) and in the current 
Spanish and European legislation on clinical studies and 
patient data confidentiality. The study will follow the 
principles of Good Clinical Practice. This study has been 
approved by the Clinical Research Ethics Committee of 
La Paz University Hospital (Madrid, Spain) and by the 
Spanish Agency of Medication and Health Products.
This clinical trial has been classified by the Spanish 
Agency for Medicines and Healthcare Products as a ‘low- 
intervention clinical trial’. The additional diagnostic or 
monitoring procedures do not pose more than minimal 
additional risk or burden to the safety of the subjects 
compared with normal clinical.
No additional use of the system for compensation shall 
be required from the sponsor for low- intervention clin-
ical trials. If any possible damage that could be suffered 
by a subject, resulting from the use of the investigational 
medicinal product in accordance with the protocol of 
that specific clinical trial, it is covered by the applicable 
compensation system already in place.
All protocol amendments will be evaluated by the 
Ethics Committee and the Spanish Agency of Medication 
and Health Products, following the principles of Good 
Clinical Practice and national legislation.
DISCUSSION
Some important barriers have been detected to imple-
mentation of pharmacogenetics in usual clinical prac-
tice. The reasons detected in the literature include the 
difficulty of obtaining high- level evidence on genetic 
markers’ efficacy, effectivity and efficiency, and a lack of 
consensus. Another problem is the absence of pharma-
cogenetic techniques’ formation and its interpretation. 
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We also have to consider the financial, logistic and legal 
limitations. Finally, there is no specific implementa-
tion strategy in clinical practice. There have been two 
proposed models for the implementation of pharmacog-
enetics biomarkers in usual clinical practice:
 ► Case- to- case model: the decision is made individually and is 
based on the need for using a drug whose effectiveness 
or safety is modified by specific genetics variations. The 
limitations are the costs and the latency between sample 
extraction and the results obtained.
 ► Pre- emptive genotyping model: this alternative assesses the 
patient’s genetic information at the very beginning, even 
before starting treatment. Currently, the development of 
arrays permits detection of a significant number of muta-
tions in which therapeutic impact is probable or definite. 
Other authors have developed a similar strategy,11 12 for 
instance, St. Jude’s Hospital,13 as well as our group.14 
Rasmussen- Torvik et al have proposed the eMERGE- PGx 
project, in which pre- emptive pharmacogenotyping is 
integrated with clinical history.15
In the case of voriconazole, several studies have linked 
CYP2C19 polymorphism to the response. In addition, 
some studies have shown that genotyping CYP2C19 is 
effective. The cost- efficiency of pretreatment genotyping 
in some drugs has been already demonstrated in some 
articles7; however, there is no evidence of voricona-
zole efficiency specifically in the Spanish NHS, or even 
whether voriconazole- related cytochrome genotyping is 
efficient in other countries.16
This pragmatic clinical trial is proposed by our group 
to evaluate effectiveness and efficiency of pre- emptive 
biomarker genotyping and its interpretation by a pharma-
cogenetic unit for patients with haematological diseases 
and a risk of fungal infection, who are susceptible to 
receiving voriconazole treatment. If our hypothesis is 
proven, this strategy will help us improve the preven-
tion and treatment of this infectious complication. This 
trial will provide information about the viability of the 
translation of this strategy to routine clinical practice. 
In addition, our pre- emptive pharmacogenetic strategy, 
combined with therapeutic drug monitoring, has the 
potential to improve efficacy and safety, with a high level 
of evidence,6 lowering the likelihood of AE occurrences.
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